Trial Profile
Post-Marketing Surveillance of Humira in Korean Pediatric CD Patients Under the "New-Drug Re-examination"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2015 New trial record